Structural and signaling research on the GLP-1 S analog
GLP-1 S is a long-acting GLP-1 receptor agonist analog studied through receptor structure, binding geometry, signaling bias, and trafficking assays.
Overview
GLP-1 S is presented by VIVO as a GLP-1 receptor agonist analog. The strongest non-clinical literature for this page concerns semaglutide: a modified peptide whose sequence and lipid side chain alter receptor engagement, albumin association, and experimental exposure relative to native GLP-1.
Cryo-electron microscopy has visualized semaglutide bound to the GLP-1 receptor–Gs complex, while cell-based studies compare cyclic-AMP production, beta-arrestin recruitment, internalization, and receptor trafficking. These methods show that receptor activation is not a single readout and that assay context can change the apparent signaling profile.
This literature supports controlled receptor-structure and signaling research. It does not mean a VIVO material has been evaluated in any cited study, and it does not establish safety, efficacy, dosing, administration, or an expected outcome in humans or animals.
References
Peer-reviewed sources for the research summarised above. Vivo summarises published, third-party science and does not conduct or sponsor this research.
- Zhang X, Belousoff MJ, Liang YL, et al. (2021). Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R–Gs complexes. Cell Reports; 36(2):109374. View source ↗
- Wu F, Yang L, Hang K, et al. (2020). Full-length human GLP-1 receptor structure without orthosteric ligands. Nature Communications; 11:1272. View source ↗
- Zhang Y, Sun B, Feng D, et al. (2017). Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature; 546:248–253. View source ↗